EPGL
MRNA icon

Evelyn Partners Group Ltd’s Moderna MRNA Stock Holding History

Evelyn Partners Group Ltd’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3K Buy
+304
New +$15.7K ﹤0.01% 435

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Evelyn Partners Group Ltd's MRNA Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Moderna (MRNA) in Q2 2026: 304 shares worth $21.3K. The stake represents ﹤0.01% of the portfolio and ranks #435 among its holdings.

399 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Evelyn Partners Group Ltd held 304 shares of Moderna worth $21.3K as of Q2 2026.
  • Moderna was a new Evelyn Partners Group Ltd position in Q2 2026.
  • Moderna made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #435 holding.
  • 399 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.